Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Net Income
Bottom-line profit after all expenses, interest, and taxes.
Accendra Health, Inc.NYSE: ACH
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$6.47M, compared with -$24.98M a year earlier. Trailing-twelve-month net income was -$1.08B.
Context
- Net income amounted to 39.8% of revenue in FY2025, up 36.5 pp from a year earlier.
- Net income increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of $1.24M (+100.1%) for the fiscal year ending Dec 2026, a step up from the -203.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.47M+88.5% QoQ
- Last fiscal yearDec 2025
- -$1.1B-203.5% YoY
- LTMMar 2026
- -$1.08B-195.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +74.1% | +99.3% | +25.2 pp |
| 1 year | -203.5% | +100.1% | +303.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (1.1B) USD
- Year-over-year change
- -203.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.1B) | -203.5% |
| FY2024 | 2024-12-31 | (362.69M) | -778.2% |
| FY2023 | 2023-12-31 | (41.3M) | -284.5% |
| FY2022 | 2022-12-31 | 22.39M | -89.9% |
| FY2021 | 2021-12-31 | 221.59M | — |
Net Income vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -195.8% is the 10th highest of 11, against a peer median of +27.9%.
- Net income amounts to 39.8% of revenue for ACH, versus a peer median of 103.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$37.25M USD | +24.6% | — | 46.8% | |
| LTM Apr 2026 | -CA$44.03M CAD | -355.0% | — | 6.6% | |
| LTM Mar 2026 | -$52.66M USD | -2.2% | — | 89.1% | |
| LTM Mar 2026 | -$69.66M USD | +46.5% | — | 832.6% | |
| LTM Mar 2026 | -$74.85M USD | +34.2% | — | 63.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.93M USD | -26.6% | — | 871.8% |
| LTM Mar 2026 | -$108.95M USD | +56.6% | — | 281.6% | |
| LTM Mar 2026 | -$173.76M USD | +31.1% | — | — | |
| LTM Mar 2026 | -$175.43M USD | -38.4% | — | — | |
| LTM Mar 2026 | -CA$366.64M CAD | +38.7% | — | 117.4% | |
| LTM Mar 2026 | -$1.08B USD | -195.8% | — | 39.8% | |
| Peer median (excluding ACH) | — | +27.9% | — | 103.3% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.79B | 9.96B | 10.33B | 10.7B | 2.76B |
| Cost of Revenue | 8.27B | 8.13B | 8.21B | 8.48B | 1.56B |
| Gross Profit | 1.51B | 1.83B | 2.13B | 2.22B | 1.2B |
| Gross Margin | 15.5% | 18.3% | 20.6% | 20.7% | 43.5% |
| Research & Development | 12.1M | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.08B | 1.55B | 1.81B | 1.91B | 1.05B |
| Operating Expenses | 1.14B | 1.68B | 2.02B | 2.43B | 1.05B |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| EBITDA | 415.47M | 368.45M | 390.57M | 51.22M | 364.68M |
| EBITDA Margin | 4.2% | 3.7% | 3.8% | 0.5% | 13.2% |
| Operating Income | 368.47M | 142.91M | 104.51M | (207.77M) | 150.16M |
| Operating Margin | 3.8% | 1.4% | 1.0% | -1.9% | 5.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 48.09M | 128.89M | 157.92M | 143.8M | 129.2M |
| Other Income / Expenses | (91.72M) | (132.02M) | (159.23M) | (149.59M) | (252.11M) |
| Income Before Tax | 276.75M | 10.89M | (54.73M) | (357.36M) | (101.95M) |
| Pre-Tax Margin | 2.8% | 0.1% | -0.5% | -3.3% | -3.7% |
| Income Tax Expense | 55.17M | (11.5M) | (13.43M) | 5.33M | 729K |
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (1.1B) |
| Net Margin | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% |
| EPS (Basic) | 3.05 | 0.30 | (0.54) | (4.73) | (14.31) |
| EPS (Diluted) | 2.94 | 0.29 | (0.54) | (4.73) | (14.31) |
| Weighted Avg Shares | 72.74M | 74.5M | 75.79M | 76.74M | 76.9M |
| Weighted Avg Shares (Diluted) | 75.49M | 76.22M | 75.79M | 76.74M | 76.9M |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.